Summary
The provided statements describe aspirin overdose symptoms and treatments, but the supplied FDA label excerpts only address stroke risk reduction and a dosing interchangeability warning. Therefore, the overdose-related content cannot be verified against the provided label text, leading to partial alignment.
Category Scores
Accurate Statements
No on-label indication statement was made in the response content provided for evaluation (the listed items were all overdose-related).
No indication claim present in the response to assess against the provided label excerpts.
Unsupported Statements
Aspirin overdose can cause stomach pain and nausea.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause vomiting blood.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause black tarry stools.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause dizziness and fainting.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause rapid heartbeat and palpitations.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause shortness of breath and difficulty breathing.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause confusion.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause drowsiness.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can cause loss of consciousness.
No overdose symptom information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to seizures and coma if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to respiratory failure if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to cardiac arrest if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to gastric bleeding if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to ulcers if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to kidney damage if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Aspirin overdose can lead to kidney failure if left untreated.
No overdose outcome information is present in the supplied FDA label excerpts.
Treatment options for aspirin overdose may include activated charcoal.
No overdose treatment information is present in the supplied FDA label excerpts.
Treatment options for aspirin overdose may include a stomach pump.
No overdose treatment information is present in the supplied FDA label excerpts.
Treatment options for aspirin overdose may include medication to stabilize vital signs.
No overdose treatment information is present in the supplied FDA label excerpts.
Contradictions
Important Omissions
No relevant on-label stroke risk reduction indication content was evaluated or stated in the overdose symptom/treatment list, so label alignment for the labeled indication cannot be demonstrated by the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The response provides overdose symptom and treatment options, but this cannot be verified against the supplied FDA label excerpts. Unverifiable content could be inaccurate relative to the provided label basis.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partial / Misaligned
Primary Issue
Overdose symptoms and treatment statements are not supported by the supplied FDA label sections (which only cover stroke risk reduction and interchangeability).
Suggested Improvement
Limit the response to claims supported by the provided label excerpts, or supply and cite the FDA label sections that address overdose (e.g., overdose/overdosage and clinical management) before asserting specific symptoms or treatments.